Fly News Breaks for September 13, 2017
Sep 13, 2017 | 07:15 EDT
SunTrust analyst John Boris says that data on the efficacy of Eli Lilly's Jardiance drug showed that it " reduces risk of cardiovascular death in type 2 diabetes patients irrespective of background blood glucose levels." The analyst thinks the data supports the use of the drug "in various (type 2 diabetes) settings." He expects the company's diabetes business to reach $10.5B in 2021, up from $4.4B in 2013. Boris keeps a $96 price target and a Buy rating on the shares.
News For LLY From the Last 2 Days
There are no results for your query LLY